G01N 2333/924
Acting on glycosyl compounds
Official title: acting on glycosyl compounds (3.2)
G01N2333/924 (Acting on glycosyl compounds) appears on 535 US grants and 684 published applications in this corpus.
Search patents in G01N- Granted patents
- 535
- Published applications
- 684
- Assignees
- 474
- Inventors
- 1,586
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 0 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 3 | 0 |
| 1982 | 5 | 0 |
| 1983 | 3 | 0 |
| 1984 | 7 | 0 |
| 1985 | 2 | 0 |
| 1986 | 2 | 0 |
| 1987 | 4 | 0 |
| 1988 | 1 | 0 |
| 1989 | 3 | 0 |
| 1990 | 3 | 0 |
| 1991 | 1 | 0 |
| 1992 | 5 | 0 |
| 1993 | 8 | 0 |
| 1994 | 9 | 0 |
| 1995 | 12 | 0 |
| 1996 | 11 | 0 |
| 1997 | 11 | 0 |
| 1998 | 6 | 0 |
| 1999 | 13 | 0 |
| 2000 | 11 | 0 |
| 2001 | 12 | 2 |
| 2002 | 7 | 11 |
| 2003 | 11 | 7 |
| 2004 | 8 | 11 |
| 2005 | 0 | 13 |
| 2006 | 4 | 19 |
| 2007 | 8 | 19 |
| 2008 | 6 | 16 |
| 2009 | 12 | 13 |
| 2010 | 9 | 30 |
| 2011 | 11 | 28 |
| 2012 | 17 | 33 |
| 2013 | 21 | 23 |
| 2014 | 22 | 43 |
| 2015 | 27 | 41 |
| 2016 | 23 | 50 |
| 2017 | 27 | 47 |
| 2018 | 25 | 34 |
| 2019 | 40 | 25 |
| 2020 | 22 | 31 |
| 2021 | 18 | 33 |
| 2022 | 17 | 23 |
| 2023 | 12 | 28 |
| 2024 | 25 | 37 |
| 2025 | 17 | 44 |
| 2026 | 9 | 23 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- G01N 2333/926Acting on alpha -1, 4-glucosidic bondsIndexing code65
- G01N 2333/938Acting on beta-galactose-glycoside bondsIndexing code49
- G01N 2333/936Acting on beta-1, 4 bonds between n-acetylmuramic acid and 2-acetyl-amino 2-deoxy-d-glucoseIndexing code23
- G01N 2333/942Acting on beta-1, 4-glucosidic bondsIndexing code18
- G01N 2333/94Acting on alpha-galactose-glycoside bondsIndexing code15
- G01N 2333/944Acting on alpha-1, 6-glucosidic bondsIndexing code2
Recent patents
- Reagents and methods for screening MPS I, II, IIIA, IIIB, IVA, VI, AND VII23 Jun 2026US 12,662,503 B2University of Washington through its Center for Commercialization
- Kidney health monitoring in hypertension patients26 May 2026US 12,638,455 B2The Regents of the University of California
- Methods of treating dementia associated with alzheimer's disease with protective protein/cathepsin A (PPCA)26 May 2026US 12,640,251 B2St. Jude Children?S Research Hospital
- Methods for detecting and inhibiting brain metastasis28 Apr 2026US 12,613,245 B2Cornell University
- PH20 polypeptide variants, formulations and uses thereof14 Apr 2026US 12,600,959 B2Halozyme, Inc.
- Ph20 polypeptide variants, formulations and uses thereof1 Oct 2026US 2026/0297551 A1Halozyme, Inc.
- Methods of determining relative unpaired glycan content1 Oct 2026US 2026/0298943 A1Amgen Inc.
- Ph20 polypeptide variants, formulations and uses thereof17 Sep 2026US 2026/0275318 A1Halozyme, Inc.
- Methods and compositions for modification and detection of 5-methylcytosine3 Sep 2026US 2026/0258487 A1The University of Chicago
- Ph20 polypeptide variants, formulations and uses thereof27 Aug 2026US 2026/0250652 A1Halozyme, Inc.
Most cited
By later US patents
- Chromogenic acridinone enzyme substrates137US 4,810,636 AMiles Inc. · 1989
- Methods for analyzing protein binding events132US 6,566,079 B2Signature BioScience, Inc. · 2003
- Fluorescent haloalkyl derivatives of reporter molecules well retained in cells110US 5,362,628 AMolecular Probes, Inc. · 1994
- Enzyme assays for a droplet actuator108US 8,202,686 B2Advanced Liquid Logic, Inc. · 2012
- Method of conducting a droplet based enzymatic assay103US 8,440,392 B2Advanced Liquid Logic, Inc. · 2013